Emergent Biosolutions (EBS) Tops Q1 EPS by 13c; Guides Q2 Sales
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $1.95 -10.55%
Revenue Growth %: +12.3%
Financial Fact:
Product sales: 96.7M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Revenue Growth %: +12.3%
Financial Fact:
Product sales: 96.7M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Join SI Premium – FREE
Emergent Biosolutions (NYSE: EBS) reported Q1 EPS of ($0.02), $0.13 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $50.3 million versus the consensus estimate of $47.32 million.
Sees Q2 2012 revenue of $70-$80 million, versus the consensus of $76.6 million.
For earnings history and earnings-related data on Emergent Biosolutions (EBS) click here.
Sees Q2 2012 revenue of $70-$80 million, versus the consensus of $76.6 million.
For earnings history and earnings-related data on Emergent Biosolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- Data I/o Corp (DAIO) Misses Q2 EPS by 7c
- Northeast Community Bancorp, Inc. (NECB) Tops Q1 EPS by 12c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
